文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术的临床试验

Clinical trials of transcatheter aortic valve replacement.
PubMed 文献 · Heart · 2019-01-01

经导管主动脉瓣置换术(TAVR)治疗重度主动脉瓣狭窄的有效性基于一系列随机对照试验(RCT)。

要点

  • TAVR在不适合手术或极高危重度主动脉瓣狭窄患者中对比药物治疗显示优效。
  • 在高危和中危外科风险患者中,TAVR对比外科主动脉瓣置换在所有研究中显示非劣效。
  • 低危患者RCT已完成入组,1年结果将于2019年初公布。

核心结论

  • TAVR是重度主动脉瓣狭窄的有效治疗选择,证据基础来自一系列随机对照试验。

主要发现

  • 初始试验在不适合手术或极高危患者中对比药物治疗,显示TAVR优效。
  • 后续RCT在高危和中危外科风险患者中对比外科主动脉瓣置换,TAVR在所有研究中显示非劣效。
  • 低危外科风险患者的RCT已完成入组,1年结果将于2019年初公布。

临床怎么用

  • TAVR可用于不适合手术或极高危的重度主动脉瓣狭窄患者。
  • 在高危和中危外科风险患者中,TAVR可作为外科主动脉瓣置换的替代选择。

局限性

  • 低危外科风险患者的RCT结果尚未公布,1年结果将于2019年初可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transcatheter aortic valve replacement(TAVR) has emerged as an effective treatment option in patients with severe aortic stenosis, in large part due to a robust evidence base generated by a series of randomised controlled trials (RCTs). During the past decade more than 15 000 patients have been randomised worldwide in nine clinical trials, mostly for regulatory approval in the USA, making it one of the most carefully scrutinised medical devices at the time of introduction into clinical practice. Initial trials were performed in inoperable or extreme risk patients compared to medical therapy and demonstrated superiority. Subsequent RCTs compared TAVR to surgical aortic valve replacement in high and intermediate surgical risk patients and TAVR was found to be non-inferior in all studies. RCTs of low surgical risk patients have completed enrolment and 1 year outcomes will be available in early 2019. The details of the trials, trial results, outcomes and remaining clinical questions are summarised in this article.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Al-Azizi K, Hamandi M, Mack M, et al. Clinical trials of transcatheter aortic valve replacement. Heart. 2019. PMID: 30846518. doi:10.1136/heartjnl-2018-313511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。